Deep transcranial ultrasound stimulation using personalized acoustic metamaterials improves treatment-resistant depression in humans
Brain Stimulation · 2025-05 · 18 (3) · 1004-1014
DOI: 10.1016/j.brs.2025.04.018 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Brain Stimulation, 2025-05. Verfasst von David Attali und 25 weiteren Autor:innen. Beteiligte Einrichtung: Institute Physics for Medicine Paris, Inserm U1273, ESPCI Paris, PSL University, CNRS UMR 8063, 75015, Paris, France; S17-18 Adult Psychiatry Departm…. Hauptthemen laut MEDLINE: Deep Brain Stimulation, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Focused Ultrasound Foundation, INSERM, Agence Nationale de Sécurité du Médicament et des Produits de Santé.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Neuromodulation of deep brain regions has shown promise for treatment-resistant depression (TRD). However, it currently requires neurosurgical electrode implantation, posing significant risks and limiting widespread use while TRD affects around 100 million people worldwide. Low-intensity transcranial ultrasound stimulation (TUS) could allow precise and non-invasive deep neuromodulation, provided that the challenge of the defocusing effects of the skull is tackled. OBJECTIVE/HYPOTHESIS: Here, we present the development of a portable and neuronavigated TUS prototype based on the use of patient-specific metamaterials (metalens) that correct for skull-induced aberrations. We then present the first application of metalens-based Transcranial Ultrasound Stimulation (mTUS) in TRD. The primary objective was to assess the safety and efficacy of mTUS targeting on individual level specific white matter tracts of the subcallosal cingulate involved in TRD. METHODS: The safety and precision of this device was addressed through a series of numerical simulations and experimental measurements on ex vivo human skulls. Five participants with TRD were included in this open-label study (ClinicalTrials.gov identifier: NCT06085950) and underwent an intensive 5-day course of mTUS with a total of 25 sessions of 5 min each. RESULTS: No serious adverse events occurred during the study. By day 5 of treatment, depression severity was reduced by an average of 60.9 % (range: [30 %-83.9 %]), and four out of five patients qualified as responders, with two of them in remission. CONCLUSIONS: This study provides first-in-human evidence of the potential of mTUS as a precise, safe and effective non-invasive neuromodulation technique for neuropsychiatric disorders involving deep brain regions, offering a safer and more accessible alternative to invasive approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute Physics for Medicine Paris, Inserm U1273, ESPCI Paris, PSL University, CNRS UMR 8063, 75015, Paris, France; S17-18 Adult Psychiatry Department, GHU Paris Psychiatrie & Neurosciences, Site Sainte-Anne, 75014, P…
- Institute Physics for Medicine Paris, Inserm U1273, ESPCI Paris, PSL University, CNRS UMR 8063, 75015, Paris, France.
- S17-18 Adult Psychiatry Department, GHU Paris Psychiatrie & Neurosciences, Site Sainte-Anne, 75014, Paris, France; Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-brain…
- S17-18 Adult Psychiatry Department, GHU Paris Psychiatrie & Neurosciences, Site Sainte-Anne, 75014, Paris, France.
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-brain Team, 75014, Paris, France.
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-brain Team, 75014, Paris, France; Department of Neuroradiology, GHU Paris Psychiatrie & Neurosciences, Site Sainte-Anne,…
Förderung
- Focused Ultrasound Foundation
- INSERM
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
Zitieren
APA
Attali, D., Tiennot, T., Manuel, T. J., Daniel, M., Houdouin, A., Annic, P., Dizeux, A., Haroche, A., Dadi, G., Henensal, A., Moyal, M., Le Berre, A., Paolillo, C., Charron, S., Debacker, C., Lui, M., Lekcir, S., Mancusi, R., Gallarda, T., …, & Plaze, M. (2025). Deep transcranial ultrasound stimulation using personalized acoustic metamaterials improves treatment-resistant depression in humans. Brain Stimulation, 18(3), 1004-1014. https://doi.org/10.1016/j.brs.2025.04.018
Vancouver
Attali D, Tiennot T, Manuel TJ, Daniel M, Houdouin A, Annic P, et al. Deep transcranial ultrasound stimulation using personalized acoustic metamaterials improves treatment-resistant depression in humans. Brain Stimulation. 2025;18(3):1004-1014. doi:10.1016/j.brs.2025.04.018
BibTeX
@article{Attali2025,
author = {Attali, David and Tiennot, Thomas and Manuel, Thomas J and Daniel, Maxime and Houdouin, Alexandre and Annic, Philippe and Dizeux, Alexandre and Haroche, Alexandre and Dadi, Ghita and Henensal, Adèle and Moyal, Mylène and Le Berre, Alice and Paolillo, Cécile and Charron, Sylvain and Debacker, Clément and Lui, Maliesse and Lekcir, Sabrina and Mancusi, Rosella and Gallarda, Thierry and Sharshar, Tarek and Sylla, Khaoussou and Oppenheim, Catherine and Cachia, Arnaud and Tanter, Mickael and Aubry, Jean-Francois and Plaze, Marion},
title = {Deep transcranial ultrasound stimulation using personalized acoustic metamaterials improves treatment-resistant depression in humans},
journal = {Brain Stimulation},
year = {2025},
volume = {18},
number = {3},
pages = {1004--1014},
doi = {10.1016/j.brs.2025.04.018}
}
EUVIMED